干扰素联合胸腺肽治疗慢性乙型肝炎62例

Observation on Efficacy of α-Interferon Combined with Thymosin on Pa- tients with Chronic Hepatitis B

目的:观察干扰素α(INF-α)联合胸腺肽治疗慢性己型肝炎(Chronic Hepatitis B,CHB)的疗效。方法:126例患者随机分为治疗组62例,给IFN-α 300万IU+胸腺肤20mg,均隔日1次;对照组64例,单用INF-α 300万IU,隔日1次,疗程均为6个月。主要观察患者治疗前后症状、体征、病毒复制指标、肝功能指标的变化。结果:①两组患者在主要症状、体征方面改善明显(x^2=7.45,P<0.05)。②疗程结束时及1年后,治疗组患者HBeAg及HBVDNA的阴转率均显著高于时照组(x^2=5.47、x^2=8.61,P<0.05、P<0.01)。结论:两药联用能明显抑制HBV复制,降低其反跳和病情复发。

Aim :To observe efficacy of α-interferon (INF-α)combined wit thymosin on patients with chronic hepatitis B (CHB). Methods: 126 patients with CHB were divided into treatment group (62 cases) and control group (64 cases), 3 Mu of INF-αcombined with 20mg of thymosin was injected intramuscularly every other day for 6 months in treatmeat group, while 3 Mu of INF-o was injected intramuscularly every other day for 6 months in control group. The main symptoms and signs of all patients were observed before and after treatment. Serum levels of ALT and AST, and HBV-DNA (measured by PCR), and HBeAg (measured by ELTSA) were tested before and after treatment. Results:①The main symptoms and signs of all patients in treatment group were improved more distinctly than that in control group. X2 = 7. 45.P>0. 05. ②Negative seroconversion rate of HBeAg and HBV-DNA in treatment group was higher than in control group at end of treatment and in a follow up period of one year (X2 = 5. 47, P<0. 05; X2 = 8. 61, P<0. 01).③The difference or ALT of AST before and after treatment in treatment group was higher than in control group (190. 99 ±11. 10U/L.147. 47±18. 60,107. 16±15. 11U/L,68. 01±8. 95U/L,respectively,P<0. 01). Conclusion:The treatment of INF-α combined with thymosin on CHB was efficient, and can reduce relapse and rebound phenomenon.